Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung CancerJames Chih‐Hsin Yang, Gongyan Chen, Takako Inoue et al.|Journal of Clinical Oncology|2024Cited by 154
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih‐Hsin Yang, Tibor Csőszi, Baohui Han et al.|Journal of Thoracic Oncology|2023Cited by 55
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind studyJames Chih‐Hsin Yang, Tibor Csőszi, Alexander Luft et al.|Annals of Oncology|2021Cited by 20